Page 13 - Patrick Wingrove News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(Reuters) -Eli Lilly on Tuesday said its recently approved obesity treatment Zepbound is now available in U.S. pharmacies and could cost $550 a month for customers whose health insurance does not cover the drug, or half the list price. Wall Street analysts expect sales of Zepbound to reach about $2 billion in 2024, and for sales of Novo Nordisk's rival obesity drug Wegovy to hit around $7.5 billion. Pfizer last week said it would not advance its highly-anticipated oral obesity drug danuglipron into late-stage clinical trials after most patients dropped out of a midstage trial with high ...

(Reuters) - Johnson & Johnson on Tuesday forecast revenue growth of 5-6% for the next year, as it banks on strong demand for cancer treatments Darzale...

Some leading US obesity specialists say they expect Eli Lilly’s powerful weight-loss drug Zepbound will produce the same or similar heart benefits as Novo Nordisk’s popular Wegovy.

Some leading U.S. obesity specialists say they expect Eli Lilly’s powerful weight-loss drug Zepbound will produce the same or similar heart benefits as Novo Nordisk’s popular Wegovy as they belong...

Novo Nordisk on Thursday said it sued one compounding pharmacy and refiled a lawsuit against another after finding their products claiming to contain the active ingredient for its in-demand weight-loss drug were impure.